DrugPatentWatch Database Preview
Alkermes Company Profile
Email this page to a colleague
What is the competitive landscape for ALKERMES, and what generic alternatives to ALKERMES drugs are available?
ALKERMES has six approved drugs.
There are twenty-five US patents protecting ALKERMES drugs.
There are two hundred and twenty-nine patent family members on ALKERMES drugs in thirty-five countries and twelve supplementary protection certificates in eight countries.
Summary for Alkermes
| International Patents: | 229 |
| US Patents: | 25 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
| Patent Litigation for Alkermes: | See patent lawsuits for Alkermes |
| PTAB Cases with Alkermes as petitioner: | See PTAB cases with Alkermes as petitioner |
| PTAB Cases with Alkermes as patent owner: | See PTAB cases with Alkermes as patent owner |
Drugs and US Patents for Alkermes
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-004 | May 28, 2021 | RX | Yes | No | 8,252,929 | ⤷ Sign up for a Free Trial | Y | ⤷ Sign up for a Free Trial | |||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | 8,796,276 | ⤷ Sign up for a Free Trial | ⤷ Sign up for a Free Trial | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | RX | Yes | No | 10,716,785 | ⤷ Sign up for a Free Trial | ⤷ Sign up for a Free Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alkermes
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,495,166 | ⤷ Sign up for a Free Trial |
| Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,667,061 | ⤷ Sign up for a Free Trial |
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | 7,956,187 | ⤷ Sign up for a Free Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Alkermes Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2019085417 | ⤷ Sign up for a Free Trial |
| Spain | 2304477 | ⤷ Sign up for a Free Trial |
| European Patent Office | 3156056 | ⤷ Sign up for a Free Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alkermes Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1675573 | 300669 | Netherlands | ⤷ Sign up for a Free Trial | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| 1675573 | 92427 | Luxembourg | ⤷ Sign up for a Free Trial | PRODUCT NAME: ARIPIPRAZOLE |
| 2316456 | LUC00054 | Luxembourg | ⤷ Sign up for a Free Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
